AC
CGTX icon

Apella Capital’s Cognition Therapeutics CGTX Stock Holding History

Apella Capital’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,200
Closed -$6.48K – 477
2025
Q2 		$6.48K Hold
11,200
– – ﹤0.01% 424
2025
Q1 		$3.66K Buy
+11,200
New +$6.58K ﹤0.01% 387

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return

Apella Capital's CGTX Position: Q3 2025 in Review

Apella Capital sold out of Cognition Therapeutics (CGTX) in Q3 2025, closing a stake of 11,200 shares — an estimated $6.48K sold.

Apella Capital first reported a position in CGTX in Q1 2025 and held it in 2 quarters. The position peaked at $6.48K in Q2 2025. 69 funds tracked by Wall St. Rank hold CGTX as of Q3 2025.

  • Apella Capital reported no remaining Cognition Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Apella Capital sold 11,200 Cognition Therapeutics shares in Q3 2025, an estimated $6.48K.
  • Apella Capital first reported a position in Cognition Therapeutics in Q1 2025 and held it in 2 quarters.
  • Apella Capital's Cognition Therapeutics position peaked at $6.48K in Q2 2025.
  • 69 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2025.

Based on Apella Capital's 13F filing for Q3 2025, filed 17 Oct 2025.